SAM #FDA-133991

FDA Sole Source Procurement: Integrated Dual-Mode Microbial Phenotypic Analysis System from Biolog Inc.

This notice announces the FDA's intent to issue a sole source contract for a specialized laboratory analysis system. - Agency: Food and Drug Administration (FDA), Department of Health and Human Services - Procurement Type: Sole source, firm-fixed price commercial purchase order - Vendor/OEM: Biolog Inc. - Product: Integrated Dual-Mode Microbial Phenotypic Analysis System - Must measure both redox respiration and optical density growth kinetics simultaneously - Must be compatible with FDA's proprietary phenotypic microarray plates and validated workflows - Justification: Market research found no alternative vendors or products meeting these requirements - NAICS Code: 334516 (Analytical Laboratory Instrument Manufacturing) - No services or additional line items specified - Commercial opportunity for similar OEMs is limited due to proprietary compatibility requirements

Description

Notice of Intent to Award a Sole Source Contract to Biolog (FDA-133991)

The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price commercial Purchase Order (PO) to Biolog Inc. 21124 Cabot Blvd., Hayward, CA  94545 for the Purchase of Integrated Dual-Mode Microbial Phenotypic Analysis System in accordance with the authority under FAR RFO Part 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. The NAICS Code for this action is 334516–Analytical Laboratory Instrument Manufacturing industry. This acquisition is being conducted using simplified acquisition procedures in accordance with FAR RFO Part 12 for the acquisition of commercial products and commercial services.

Biolog is the only manufacturer of the Integrated Dual-Mode Microbial Phenotypic Analysis System that is uniquely capable of integrating with the FDA's existing maintaining compatibility with phenotypic microarray plates and validated workflows. Market research did not identify any alternative analyzers capable of providing an integrated platform that simultaneously measures redox respiration and optical density growth kinetics, compatibility with proprietary phenotypic microarray plates currently in use.

This notice is not a request for competitive quotes. Any other firms desiring consideration must fully identify their interest and capability of meeting the requirements by submitting a capability statement to Janice Heard at janice.heard@fda.hhs.gov no later than July 09, 2026. Any response shall undergo review to determine if it can meet the requirements. A determination by the Government not to compete this proposed requirement based upon a response to this notice is solely within the discretion of the Government.

View original listing